Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia

HONG KONG, Dec. 8, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III…